The presence of atrial-natriuretic-factor receptors of ANF-R2 subtype in rat platelets. Coupling to adenylate cyclase/cyclic AMP signal-transduction system.
The effect of atrial natriuretic factor (ANF) on adenylate cyclase activity was studied in rat platelet membranes. ANF-(99-126)-, -(101-126)-, -(103-126)- and -(103-123)-peptide inhibited adenylate cyclase activity in a concentration-dependent manner with an order of potency of ANF-(103-123)-peptide greater than ANF-(99-126)-peptide greater than ANF-(101-126)-peptide greater than ANF-(103-126)-peptide. ANF-(103-123)-peptide and ANF-(99-126)-peptide inhibited the enzyme activity by about 50-55%, with an apparent Ki between 0.1 and 0.5 nM, and ANF-(101-126)-peptide inhibited the enzyme activity by about 35%, with an apparent Ki between 1 and 3 nM. On the other hand, ANF-(103-126)-peptide was the least potent and inhibited the adenylate cyclase activity by about 30% (Ki approximately 10 nM). The inhibitory effect of ANF on adenylate cyclase was also dependent on the presence of guanine nucleotides and was attenuated by amiloride and pertussis toxin. The stimulatory effects of various agonists such as N-ethylcarboxamideadenosine, prostaglandin E1, isoprenaline and forskolin on adenylate cyclase were also inhibited by ANF to various extents; however, the stimulations were not completely abolished. In addition, 125I-labelled ANF-(99-126)-peptide bound specifically to rat platelet membranes. The binding of 125I-ANF was competitively inhibited in a concentration-dependent manner by the unlabelled peptides which were used for adenylate cyclase inhibition. ANF-(103-123)-peptide, ANF-(99-126)-peptide and ANF-(101-126)-peptide were almost equipotent [IC50 (median inhibitory concentration) = 0.1-1 nM], and ANF-(103-126)-peptide was the least potent (IC50 approximately 10 nM). Scatchard analysis of the data revealed the presence of a single class of binding sites of high affinity (Kd approximately 120 pM). Affinity cross-linking of 125I-ANF-(99-126)-peptide to its binding sites in rat platelet membranes and analysis by SDS/PAGE followed by autoradiography showed a predominant labelling of a protein band with an apparent Mr of 66,000. These data indicate the presence of only ANF-R2 (low-Mr) receptors in platelets and suggest that these receptors may be coupled to the adenylate cyclase system.
Anand-Srivastava
M B
MB
Clinical Research Institute of Montreal, Quebec, Canada.
Gutkowska
J
J
Cantin
M
M
D037361:Adenylate Cyclase Toxin; D000067956:Adenylyl Cyclase Inhibitors; D000584:Amiloride / Q000494:pharmacology; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000378:metabolism / Q000494:pharmacology; D001667:Binding, Competitive; D001792:Blood Platelets / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D003432:Cross-Linking Reagents; D000242:Cyclic AMP / Q000378:metabolism; D006150:Guanine Nucleotides / Q000494:pharmacology; D010446:Peptide Fragments / Q000378:metabolism / Q000494:pharmacology; D037342:Pertussis Toxin; D051381:Rats; D017461:Receptors, Atrial Natriuretic Factor; D011956:Receptors, Cell Surface / Q000378:metabolism*; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D037361:Adenylate Cyclase Toxin; D000067956:Adenylyl Cyclase Inhibitors; D003432:Cross-Linking Reagents; D006150:Guanine Nucleotides; D010446:Peptide Fragments; D011956:Receptors, Cell Surface; D010566:Virulence Factors, Bordetella; C472610:atrial natriuretic peptide, rat; D000584:Amiloride; D009320:Atrial Natriuretic Factor; D000242:Cyclic AMP; D037342:Pertussis Toxin; D017461:Receptors, Atrial Natriuretic Factor